ArriVent Pharmaceuticals Science
Programs
ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of $18.00 per share. All of the shares of common stock are being offeredRead More
ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Winston Kung as Chief Financial Officer and Treasurer. Mr. Kung brings over 20 years of extensive leadership experience to ArriVent, most recently serving as Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals.Read More
ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factorRead More
ArriVent BioP-harma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Chris Nolet to its Board of Directors. Mr. Nolet has extensive leadership experience as an audit partner, business advisor and independent board director in the life sciences industry, and currently serves on the BoardsRead More
Allist Pharmaceuticals Co., Ltd. (“Allist”) and ArriVent Biopharma, Inc. (“ArriVent”) together announced that interim results from the Phase Ib, randomized, open-label, multi-center clinical study (FAVOUR), evaluating the efficacy and safety of furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, were presented by Professor BaohuiRead More
BEIJING, China, July 14, 2023, and NEWTOWN SQUARE, PA, U.S. July 13, 2023 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases and ArriVent Biopharma, a clinical stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced a clinical developmentRead More
NEWTOWN SQUARE, PA—March 27, 2023—ArriVent Biopharma, Inc., dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the completion of a $155 million oversubscribed Series B financing. The proceeds will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate furmonertinib – a highly brain penetrant, mutant-specificRead More
ArriVent Biopharma, Inc., dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been enrolled in its Phase 1b trial of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) or HER2 mutations, including exon 20 insertion mutations.Read More
ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment of Bahija Jallal, Ph.D. to its Board of Directors. Dr. Jallal has more than 25 years of experience across research and clinical development, operations, regulatory, commercialization and finance, and currently serves as Chief Executive Officer and Director ofRead More